LAKE FOREST, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- InMode Ltd., a leading global provider of innovative, energy-based, minimally invasive solutions, announces the publication of the results of its new combined protocol for the treatment of skin laxity. Published in the Aesthetic Surgery Journal (ASJ), the results illustrate the effects of InMode’s Morpheus8, a subdermal adipose remodeling device (SARD) with adjustable depth, combined with FaceTite, a minimally invasive radiofrequency-based technology for the treatment of fat.
Morpheus8, one of InMode’s newest products, is a fractional radiofrequency device with adjustable microneedles up to 4 mm depth, programmable according to the treatment area. The combination of Morpheus8 with FaceTite, InMode’s clinically proven Radio-Frequency Assisted Lipolysis (RFAL) device for the treatment of facial and body areas, shows significant skin contraction and subdermal adipose remodeling. The combination of these two treatments is called EmbraceRF. The procedure is a solution for the population of “treatment gap” patients who do not want major surgery, are too young, or whose condition does not yet require a full face or neck lift. The article highlights clinical applications, such as early facial aging, recurrent laxity after a facelift, brachioplasty, and focal areas of excess skin adiposity.
Moshe Mizrahy, co-founder and CEO of InMode, comments, “We understand our patient’s desire for effective skin contraction treatments without the need to undergo major surgery, which led to the development of this combination protocol.” He continues, “This publication, written by leading plastic surgeons such as Dr. Erez Dayan, Dr. Chris Chia, Dr. Jay Burns, and Dr. Spero Theodorou, demonstrates the effectiveness of our combined minimally invasive and RF fractional technologies.”
“EmbraceRF is a novel procedure for subdermal adipose-remodeling of the face,”says President of North America, Shakil Lakhani. “We believe this new concept for facial rejuvenation can be performed consistently and safely with best possible outcomes for patients. These are key elements in our commitment to providing medical breakthroughs.”
About InMode
InMode Ltd. is a leading global provider of innovative medical technologies. InMode develops, manufacturers, and markets devices harnessing novel radio-frequency (RF) based devices. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For additional information, visit www.inmodemd.com.
Press Contact:
Behrman Communications
Amanda Reinstein
areinstein@behrmanpr.com